On September 21, 2023, the Federal Trade Commission (FTC) brought a suit against Welsh, Carson, Anderson & Stowe (WCAS) and U.S. Anesthesia Partners, Inc. (USAP), alleging both parties for carrying out an anticompetitive scheme over several years. The FTC filed the case in the Southern District of Texas, stating the companies aimed to consolidate anesthesiology practices across Texas, subsequently driving up the price of anesthesia services for Texas patients and boosting their own respective profits. Read Full Report
The suit implicates the defendants in potentially serious antitrust violations, reflecting the FTC’s continued commitment to combat harmful corporate behavior in healthcare markets. The case also serves as a reminder to legal professionals of the FTC’s heightened focus on the comprehensive role of private equity firms in anticompetitive transactions, requiring thorough understanding and navigation of an increasingly complex regulatory landscape.
The FTC’s increasing scrutiny on private equity’s role in allegedly anticompetitive healthcare transactions is worth noting, given the potentially far-reaching implications for mergers and acquisitions activity in the sector. However, the case is an important signal to legal professionals that vigilance in antitrust analysis, and risk assessment are pivotal to establishing and running successful healthcare operational strategies.
While the outcome of the lawsuit remains uncertain, the ongoing case demonstrates the need for both large corporations and law firms to keep abreast of the rigorous antitrust inspection from regulatory bodies. As global legal professionals, it points to the relevance of maintaining regulatory compliance, and the importance of continuous learning and adaptation in today’s complex legal environment.